腎芽腫治療市場：タイプ別、薬剤タイプ別、流通チャネル別：地域別

世界の腎芽腫治療市場は、2025年には18億7,000万米ドルと推定され、2032年には26億3,000万米ドルに達すると予測され、2025年から2032年にかけてCAGR5.0％で成長する見込みです。

図.腎芽腫治療市場シェア（%）、2025年地域別

ウィルムス腫瘍としても知られる腎芽腫は、小児に発生する最も一般的な固形腫瘍のひとつです。腎芽細胞腫は腎臓に発生し、小児がん全体の約6%を占める。腎芽腫の標準的な治療法としては、腫瘍の外科的切除が行われ、その後、残存するがん細胞を除去するために化学療法が行われることが多いです。最近の手術手技、化学療法レジメン、および標的療法の進歩により、腎芽腫と診断された小児の生存率は著しく改善されています。しかし、耐性腫瘍の開発は市場の成長を妨げる可能性があります。腎芽腫治療市場は、治療効果と治療成績を向上させる革新的な製品に対する需要の高まりによって成長する可能性があります。

市場力学

腎芽腫治療市場の成長は、主に世界の小児の腎臓がん罹患率の上昇によってもたらされます。セント・ジュード小児研究病院が2022年に発表したデータによると、腎芽細胞腫は新生児約13,000人に1人が罹患し、小児がん全体の6～7%を占めています。診断能力の向上と早期発見に関する意識の高まりにより、ヘルスケアプロバイダーはより早い段階でこの疾患を診断できるようになり、その結果、効果的な治療薬に対する需要が高まっています。しかし、手術や長期にわたる化学療法に伴う高コストが市場成長の妨げとなる可能性があります。新規の標的療法や薬剤の組み合わせに関する継続的な研究は、耐性腫瘍をより効率的に治療するための有望な機会を保持しています。

本調査の主な特徴

本レポートでは、世界の腎芽腫治療市場を詳細に分析し、2024年を基準年とした予測期間（2025-2032年）の市場規模およびCAGRを掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案マトリクスについて解説しています。

また市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。

世界の腎芽腫治療市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。

本調査の対象となる主要企業には、Merck &Co.社、ファイザー社、Sun Pharmaceutical Industries Ltd.社、Actiza Pharmaceutical Private Limited社、Teva Pharmaceutical Industries Ltd.社、Alvogen社、Accord Healthcare Ireland Ltd.社、Amneal Pharmaceuticals LLC.社、Cadila Pharmaceuticals Ltd.社、Xediton Pharmaceuticals社が含まれます。

本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。

世界の腎芽腫治療市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。

利害関係者は、世界の腎芽腫治療市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向分析

• 市場力学
• 影響分析
• 主なハイライト
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• PORTERの分析
• 合併と買収のシナリオ
• 疫学

第4章 腎芽腫治療市場、タイプ別、2020年～2032年、（10億米ドル）

• 予後良好の組織型
• 腎芽腫不全型

第5章 腎芽腫治療市場、薬剤タイプ別、2020年-2032年、（10億米ドル）

• ダクチノマイシン（コスメゲン）
• ドキソルビシン（アドリアマイシン）
• ビンクリスチン（ビンカサールPFS、オンコビン）
• シクロホスファミド（サイトキサン、ネオサール）
• エトポシド（トポサール、ベペシド）
• イリノテカン（カンプトサール）
• その他

第6章 腎芽腫治療市場、流通チャネル別、2020年～2032年、（10億米ドル）

• 病院薬局
• 小売薬局
• オンライン薬局

第7章 腎芽腫治療市場、地域別、2020年-2032年、（10億米ドル）

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第8章 競合情勢

• Merck & Co., Inc.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Actiza Pharmaceutical Private Limited
• Teva Pharmaceutical Industries Ltd.
• Alvogen
• Accord Healthcare Ireland Ltd.
• Amneal Pharmaceuticals LLC.
• Cadila Pharmaceuticals Ltd.
• Xediton Pharmaceuticals

第9章 アナリストの推奨事項

• 機会
• アナリストの見解
• Coherent Opportunity Map

第10章 参考文献と調査手法

• 参考文献
• 調査手法
• 出版社について

Global Nephroblastoma Treatment Market is estimated to be valued at USD 1.87 Bn in 2025 and is expected to reach USD 2.63 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.0% from 2025 to 2032.

Figure. Nephroblastoma Treatment Market Share (%), By Region 2025

Nephroblastoma, also known as Wilms' tumor, is one of the most common solid tumors occurring in children. It originates from nephrogenic rests in the kidneys and accounts for approximately 6% of all childhood cancers. The standard treatment approach for nephroblastoma involves surgical resection of the tumor, often followed by chemotherapy to eliminate any remaining cancer cells. Recent advancements in surgical techniques, chemotherapy regimens as well as targeted therapies have significantly improved the survival rates of children diagnosed with nephroblastoma. However, development of resistant tumors can hamper the market growth. Nephroblastoma treatment market can witness growth due to increasing demand for innovative products that can enhance treatment effectiveness and outcomes.

Market Dynamics

Nephroblastoma treatment market growth is primarily driven by rising incidence of kidney cancer in children worldwide. As per the data published by St. Jude Children's Research Hospital in 2022, nephroblastoma affects approximately 1 in 13,000 newborns and accounts for 6-7% of all childhood cancers. Improved diagnostic capabilities and increasing awareness regarding early detection enables healthcare providers to diagnose the condition at earlier stages, thus, boosting demand for effective therapeutics. However, high costs associated with surgery and prolonged courses of chemotherapy can hamper the market growth. Ongoing research into novel targeted therapies and drug combinations hold promising opportunities for treating resistant tumors more efficiently.

Key features of the study

This report provides in-depth analysis of the global nephroblastoma treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global nephroblastoma treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Merck & Co., Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global nephroblastoma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nephroblastoma treatment market

Market Segmentation

• By Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Favorable histology
  • Anaplastic histology
• By Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Dactinomycin (Cosmegen)
  • Doxorubicin (Adriamycin)
  • Vincristine (Vincasar PFS, Oncovin)
  • Cyclophosphamide (Cytoxan, Neosar)
  • Etoposide (Toposar, VePesid)
  • Irinotecan (Camptosar)
  • Others
• By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Actiza Pharmaceutical Private Limited
  • Teva Pharmaceutical Industries Ltd.
  • Alvogen
  • Accord Healthcare Ireland Ltd.
  • Amneal Pharmaceuticals LLC.
  • Cadila Pharmaceuticals Ltd.
  • Xediton Pharmaceuticals

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Nephroblastoma Treatment Market, By Type
  • Nephroblastoma Treatment Market, By Drug Type
  • Nephroblastoma Treatment Market, By Distribution Channel
  • Nephroblastoma Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology

4. Nephroblastoma Treatment Market, By Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Favorable histology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Anaplastic histology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Nephroblastoma Treatment Market, By Drug Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Dactinomycin (Cosmegen)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Doxorubicin (Adriamycin)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Vincristine (Vincasar PFS, Oncovin)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cyclophosphamide (Cytoxan, Neosar)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Etoposide (Toposar, VePesid)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Irinotecan (Camptosar)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Nephroblastoma Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Nephroblastoma Treatment Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Actiza Pharmaceutical Private Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Alvogen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Accord Healthcare Ireland Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amneal Pharmaceuticals LLC.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cadila Pharmaceuticals Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Xediton Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us